Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

MGI Tech and Predica Diagnostics Collaborate for Precision RNA Sequencing in Oncology

NextEdge Admin

11 Jul 2024

2 min 45 sec

Oncology,Precision Medicine,Molecular Diagnostics,Next-generation sequencing

MGI Tech, a leader in life science innovation, has announced a collaboration with Predica Diagnostics to develop Predica's targeted RNA sequencing tests using MGI's cost-effective next-generation sequencing (NGS) platforms. This partnership aims to revolutionize molecular diagnostics by enabling early cancer detection and personalized treatment strategies. Predica Diagnostics is renowned for its ciRNAseq-based test, CervicaDx, which offers precise identification of high-risk HPV oncogenes and other biomarkers. By integrating Predica's advanced assays with MGI's robust DNBSEQ technology, the collaboration seeks to enhance diagnostic accuracy and accessibility.

A key goal of this partnership is to make high-quality diagnostic testing more affordable. MGI’s DNBSEQ platforms, known for their cost-efficiency and scalability, will allow healthcare institutions to offer advanced genomic testing at lower costs, providing faster results compared to existing technologies. This integration will aid researchers and healthcare professionals in better predicting patient prognosis and guiding precision medicine treatments.

Dr. William Leenders, CSO of Predica Diagnostics, emphasizes the synergy between Predica's diagnostic solutions and MGI's sequencing platforms, which will provide clinically important gene expression information without requiring on-site bioinformatics expertise. Dr. Yong Hou, General Manager of MGI Europe and Africa, highlights the partnership's potential to advance personalized medicine by combining MGI's high-performance sequencing technology with Predica's diagnostic kits.

MGI, founded in 2016, focuses on developing and manufacturing instruments, reagents, and products in life science and biotechnology, serving customers worldwide.

Predica Diagnostics, a Radboud UMC spinoff, specializes in diagnostics, prognostics, and treatment response prediction in oncology, with a focus on non-invasive cervical cancer screening and other diagnostic tests in development. This collaboration aims to bring advanced molecular diagnostics to patients within the next one to two years, starting with the CervicaDx test.